Abstract
Consumer extended-reality (XR) glasses could provide controlled ocular light exposure, but their settings do not specify the light delivered at the eye. We developed and validated a calibration pipeline linking display control, corneal-plane spectroradiometry, settings-to-exposure modeling, and rendered application content for a see-through binocular micro-OLED display (VITURE Luma Ultra). Automated measurements characterized color channels, digital codes, hardware brightness levels, and duty-cycle settings across repeated fittings on a phantom head. The blue primary peaked at 459 nm with no resolved spectral shift across intensity settings. Blue melanopic equivalent daylight illuminance (EDI) ranged from 14.7 to 252 lx across hardware brightness levels, while full white delivered 269 lx melanopic EDI at its highest usable setting, exceeding the 250 lx daytime recommendation for healthy adults. A model calibrated on separate sessions predicted melanopic EDI for held-out codes, brightness levels, and color mixtures with a mean absolute percentage error of 3.4% (4.5% for photopic illuminance), allowing exposure to be estimated from logged display settings without remeasuring each uniform stimulus. Rendered application frames revealed position- and illuminated-area-dependent exposure; a spatial correction derived from an independent display grid accounted for these effects and closely reproduced measured frame exposure. Together, these results establish a reusable workflow for converting see-through XR hardware into a quantitatively specified ocular-light platform.
Competing Interest Statement
M.G. was previously a founder of Gamma Light Therapy LLC, a consumer light-therapy company, and holds no current financial or advisory interest in the company. The authors declare no other competing interests.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This revision replaces the measurement chain of v1 (posted August 31, 2026) and broadens the manuscript from a single-device dose characterization to a reusable calibration workflow, now titled "A calibration pipeline for controlled ocular photostimulation with consumer see-through extended-reality glasses." The open-source miniature spectroradiometer and its smartphone-anchored luminance transfer calibration (10 to 20% absolute uncertainty) have been replaced by a factory-calibrated, cosine-corrected spectroradiometer (UPRtek MK350S) at the corneal plane of a phantom head. All values are therefore reported as corneal-plane exposure, the quantity used by CIE S 026 and the consensus recommendations, and the model-eye retinal dose estimates have been removed. Characterization was repeated over three sessions with the glasses reseated between them, and repeatability is reported within captures, within sessions, and between sessions. Duty cycle, which v1 only logged, is now characterized as a third independent intensity control. Several values changed with the new measurements: the blue primary peaks at 459 nm with a FWHM of 34.7 nm (v1: 461 nm and 43 nm); full-code blue delivers 252 lx melanopic EDI (v1: 299 lx); the red melanopic DER is 0.018 (v1: 0.10); white reaches 81 to 89% of the sum of its primaries and cannot be run at the top brightness level; and the blue-light hazard of full-code blue is about a factor of 3 below the conservative small-source screening criterion. Two analyses are new. First, a settings-to-exposure model, calibrated on separate sessions and tested on an independent held-out session, predicts melanopic EDI and photopic illuminance from code, brightness level, and duty cycle with mean absolute percentage errors of 3.4% and 4.5%, and is released as a versioned calibration package. Second, rendered application frames showed that exposure depends on where pixels are and how much of the display is lit, and a spatial correction derived from an independent 3×3 display grid substantially improved agreement with measured frame exposure. Finally, the gate-based structure was replaced by a control, measure, calibrate, validate, and apply framing; terminology was clarified for non-specialist readers; figures were restructured; reference tables were moved to appendices; and the future-work list became a Scope and limitations section.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.





